Quick Answer
Inhibikase Therapeutics, Inc. reported Total Assets of $181.20 million for fiscal year 2025.
Inhibikase Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $181.20M | +83.8% |
| 2024 | $98.60M | +579.7% |
| 2023 | $14.51M | -41.8% |
| 2022 | $24.94M | -41.3% |
| 2021 | $42.47M | +187.3% |
| 2020 | $14.78M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $79.59M | +1718.5% | -10.4% |
| June 30, 2025 | $88.85M | +906.6% | -5.8% |
| March 31, 2025 | $94.28M | +751.8% | -4.4% |
| December 31, 2024 | $98.60M | +579.7% | +2152.7% |
| September 30, 2024 | $4.38M | -75.5% | -50.4% |
| June 30, 2024 | $8.83M | -60.5% | -20.3% |
| March 31, 2024 | $11.07M | -60.7% | -23.7% |
| December 31, 2023 | $14.51M | -41.8% | -18.9% |
- Inhibikase Therapeutics, Inc. showed an increase of +83.8% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Inhibikase Therapeutics, Inc.’s total assets has grown by 1125.8% (from $14.78 million to $181.20 million).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: